pamidronate has been researched along with sirolimus in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL | 1 |
| Abdelaziz, DM; Komarova, SV; Stone, LS | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Akers, LJ; Anthony, MD; Fierke, S; Heym, K; Jiwani, ZM; Margraf, LR; Ray, A; Swilling, A | 1 |
2 review(s) available for pamidronate and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Multidisciplinary Multiagent Treatment of Complex Lymphatic Anomalies with Severe Bone Disease: A Single-Site Experience.
Topics: Bone Diseases; Female; Humans; Lymphatic Abnormalities; Pamidronate; Sirolimus; Vincristine | 2022 |
3 other study(ies) available for pamidronate and sirolimus
| Article | Year |
|---|---|
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus | 2004 |
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Osteolysis; Pain; Pain Measurement; Pamidronate; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |